CN107753567A - A kind of fatigue-resistant drug composition and preparation method and application - Google Patents
A kind of fatigue-resistant drug composition and preparation method and application Download PDFInfo
- Publication number
- CN107753567A CN107753567A CN201610688954.5A CN201610688954A CN107753567A CN 107753567 A CN107753567 A CN 107753567A CN 201610688954 A CN201610688954 A CN 201610688954A CN 107753567 A CN107753567 A CN 107753567A
- Authority
- CN
- China
- Prior art keywords
- antifatigue
- pharmaceutical composition
- medicine
- preparation
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
- A61K36/296—Epimedium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/41—Crassulaceae (Stonecrop family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/64—Orobanchaceae (Broom-rape family)
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a kind of anti-fatigue medicament combination and preparation method thereof, said composition includes barrenwort, rhodiola root, ginkgo leaf, saline cistanche, and its specific preparation technology is as follows：Solvent is added after the material combination of above-mentioned anti-fatigue medicament is pulverized and sieved, decocts, filter, being concentrated under reduced pressure to give clear cream, antifatigue active principle is obtained after drying.The present invention can extract antifatigue active principle from anti-fatigue medicament combination to greatest extent, prove there is antifatigue effect through pharmacological testing, it is possible to increase immunity of organisms, improve organism metabolism level, tolerance of the enhancing body in excess load.
Description
Technical field
The invention belongs to field of traditional Chinese medicine pharmacy, is related to a kind of fatigue-resistant drug composition and its preparation method and application.
Background technology
Fatigue syndrome be chronic fatigue syndrome (Chronic Fatigue Syndrome, CFS) be one group with continue
Or the fatigue of recurrent exerbation, with a variety of nerves, mental symptom, but without the syndrome with the characteristics of organic and psychotic disorder.
Its symptom include have a fever, have a sore throat, enlargement of lymph nodes, it is extremely tired, lose appetite, recurrent upper respiratory tract infection, small intestine not
Suitable, yellow subcutaneous ulcer, anxiety, depression, agitation and emotional lability, interruptions of sleep, to light and it is thermo-responsive, be temporarily lost with memory, Wu Faji
Middle notice, headache, spasm, muscle and arthralgia.These symptoms are similar to flu and other viral infection, therefore easily by mistake
Sentence.With the development of the society, the high speed development of science and technology, the life of people are also being accelerated with work rhythm, stress, born at heart
Load is increasingly heavier, thus brings the muscle power overdraw of people, falls, chronic fatigue syndrome is more and more more.According to
Adult human male of the report with this kind of disease is close to 20%, and women is close to 25%.And due to chronic fatigue syndrome the cause of disease not
Clearly, also it is not very good although there is Remeron currently without certain effective medicine.Usual doctor understands mistaken diagnosis
For body illness caused by hypochondria, depression or spirit.It there is no and tackle this sick medicine or vaccine, recognize this disease and be not easy to,
And the change of its symptom is very greatly.
The content of the invention
The technical problems to be solved by the invention are to overcome the medicine for treating burnout syndrome in the prior art to lack, effect
The defects of undesirable and a kind of fatigue-resistant drug composition is provided.
It is a further object of the present invention to provide the preparation method of said composition.
It is yet another object of the invention to provide the application of composition.
The purpose of the present invention can be achieved through the following technical solutions：
A kind of antifatigue pharmaceutical composition, is made up of the material medicine of following weight/mass percentage composition：Barrenwort 3%~
80%, rhodiola root 3%~70%, ginkgo leaf 3%~70%, saline cistanche 3%~70%, and the weight/mass percentage composition of each raw material it
With for 100%.
Described antifatigue pharmaceutical composition, is preferably made up of the material medicine of following weight/mass percentage composition：Barrenwort
10%~60%, rhodiola root 10%~50%, ginkgo leaf 10%~50%, saline cistanche 10%~50%, and the quality of each raw material
Percentage composition sum is 100%.
Described antifatigue pharmaceutical composition, is further preferably made up of the material medicine of following weight/mass percentage composition：
Barrenwort 40%, rhodiola root 25%, ginkgo leaf 20%, saline cistanche 15%.
Described antifatigue pharmaceutical composition, it is preferably mainly molten by being added after the raw material of formula ratio is pulverized and sieved
Agent, decoct, filter, being concentrated under reduced pressure to give medicinal extract, the anti-Fatigue Composition described in drying to obtain.
The preparation method of antifatigue pharmaceutical composition of the present invention, is comprised the steps of：
(1) raw material is pulverized and sieved, adds Extraction solvent, and at 40~100 DEG C of temperature, extract 1~3 time, every time 0.5
~3 hours, obtain extract solution；Wherein the ratio between material quality and Extraction solvent volume are 1g：8~12mL；
(2) extract solution is merged, filtered, concentrated, spray-dried, reduced vacuum is dry or lyophilized, obtains dry extract；
(3) dry extract that will be obtained, crush, cross the mesh sieve of 80 mesh~100, produce described antifatigue pharmaceutical composition.
Wherein, the Extraction solvent described in step (1) preferably is selected from water or organic solvent, and described organic solvent is further preferred
Petroleum ether, ethyl acetate, the one or more in chloroform and ethanol；The preferred Microwave Extraction of described extracting method, refluxing extraction
Or means of supercritical extraction.
Application of the antifatigue pharmaceutical composition of the present invention in the medicine for preparing treatment apocamnosis.
A kind of medicine for being used to treat apocamnosis, includes pharmaceutical composition of the present invention.
Described medicine is preferably mixed by pharmaceutical composition of the present invention with pharmaceutically acceptable auxiliary material, system
Standby obtained any one formulation clinically allowed.
Described formulation preferably is selected from decoction, granule, capsule, tablet, mixture, pill or powder.
Agents useful for same and raw material of the present invention are commercially available.
Beneficial effect：
The principle active component icariin of barrenwort, it can significantly extend mouse swimming time, significantly reduce in serum
ALT, AST activity and MDA, BUN content and LDH total activities, epimedium brevicornum polysaccharide can significantly extend mouse swimming time and often
Press the resist oxygen lack time-to-live；Rhodiola root can significantly improve animal swimming endurance, hypoxia-bearing capability, increase liver, muscle glycogen content,
GSH-Px, SOD, SDH, LDH activity, reduce blood plasma, cardiac muscle, brain LPO contents；Ginkgo leaf can remove free radical, improve heart and brain
Metabolism, improve hypoxia-bearing capability；Saline cistanche can improve SOD contents, reduce MDA contents, prevent peroxidization, protect cell
Film, maintain hepatocyte cell structure, function it is normal, and then improve body movement ability, slow down physical demands.In above-mentioned 4 taste
Medicine is combined, and can play the effect of antifatigue from different approach.The invention has the advantages that anti-fatigue medicament combination can be most
Antifatigue active principle is extracted to limits from anti-fatigue medicament combination, proves that there is antifatigue work through pharmacological testing
With, it is possible to increase immunity of organisms, improve organism metabolism level, tolerance of the enhancing body in excess load.
In following pharmacological testings, influence of the fatigue-resistant drug composition to mouse anti-reflecting fatigue has mainly been investigated.
1. experiment material
1.1 animal
Kunming mouse, male, cleaning grade, 18~22g of body weight.
1.2 medicines and reagent
Absolute ethyl alcohol：Nanjing Chemistry Reagent Co., Ltd.；
Glacial acetic acid：Nanjing Chemistry Reagent Co., Ltd.；
1.3 instrument
Electronic balance, Mei Teletuo benefit scientific instrument (Shanghai) Co., Ltd..
Ultraviolet specrophotometer UV~2550, Japanese Shimadzu Corporation.
Electronic thermostatic water-bath DK~S26, type, the upper grand experimental facilities Co., Ltd of Nereid；
CENTRIFUGE5804R refrigerated centrifuges, Eppendorf companies.
2. experimental method
2.1 packets are set with dosage
Blank group：Give distilled water, 20mL/kg (body weight) oral gavage；
Model group：Give distilled water, 20mL/kg (body weight) oral gavage；
Low content group：Barrenwort 80g after pulverizing and sieving, rhodiola root 50g, ginkgo leaf 40g, saline cistanche 30g add 2L
Water boiling and extraction 2 times, 1.5 hours every time, filtering, merging filtrate, be concentrated under reduced pressure relative density be 1.3 medicinal extract；Gained
Medicinal extract reduced vacuum at a temperature of 70 DEG C it is dry dry extract, crushed 90 mesh sieves, produce pharmaceutical composition.It is every according to mouse
1kg body weight gives this group of preparation 0.160g standard, distilled water wiring solution-forming, 20mL/kg (body weight) oral gavage；
Middle content groups：Drug regimen composition formula and preparation method give this group according to mouse with low content group per 1kg body weight
Preparation 0.319g standard, distilled water wiring solution-forming, 20mL/kg (body weight) oral gavage；
High content group：Drug regimen composition formula and preparation method give this group according to mouse with low content group per 1kg body weight
Preparation 0.638g standard, distilled water wiring solution-forming, 20mL/kg (body weight) oral gavage；
A1 groups：Lack barrenwort, rhodiola root 50g, ginkgo leaf 40g, saline cistanche 30g；Above composition is according to above-mentioned preparation method
Preparation is made, gives this group of preparation 0.638g standard, distilled water wiring solution-forming, 20mL/kg (bodies per 1kg body weight according to mouse
Oral gavage again)；
A2 groups：Lack rhodiola root, barrenwort 80g, ginkgo leaf 40g, saline cistanche 30g；Above composition is according to above-mentioned preparation method
Preparation is made, gives this group of preparation 0.638g standard, distilled water wiring solution-forming, 20mL/kg (bodies per 1kg body weight according to mouse
Oral gavage again)；
A3 groups：Lack ginkgo leaf, barrenwort 80g, rhodiola root 50g, saline cistanche 30g；Above composition is according to above-mentioned preparation method
Preparation is made, gives this group of preparation 0.638g standard, distilled water wiring solution-forming, 20mL/kg (bodies per 1kg body weight according to mouse
Oral gavage again)；
A4 groups：Misrun desert cistanche, barrenwort 80g, rhodiola root 50g, ginkgo leaf 40g；Above composition is according to above-mentioned preparation method
Preparation is made, gives this group of preparation 0.638g standard, distilled water wiring solution-forming, 20mL/kg (bodies per 1kg body weight according to mouse
Oral gavage again)；
A5 groups：Lack barrenwort, rhodiola root, ginkgo leaf 40g, saline cistanche 30g；Above composition is made according to above-mentioned preparation method
Preparation, this group of preparation 0.638g standard, distilled water wiring solution-forming, 20mL/kg (body weight) warps are given per 1kg body weight according to mouse
Mouth gavage；
A6 groups：Lack barrenwort, ginkgo leaf, rhodiola root 50g, saline cistanche 30g；Above composition is made according to above-mentioned preparation method
Preparation, this group of preparation 0.638g standard, distilled water wiring solution-forming, 20mL/kg (body weight) warps are given per 1kg body weight according to mouse
Mouth gavage；
A7 groups：Lack barrenwort, saline cistanche, rhodiola root 50g, ginkgo leaf 40g；Above composition is made according to above-mentioned preparation method
Preparation, this group of preparation 0.638g standard, distilled water wiring solution-forming, 20mL/kg (body weight) warps are given per 1kg body weight according to mouse
Mouth gavage；
A8 groups：Lack rhodiola root, ginkgo leaf, barrenwort 80g, saline cistanche 30g；Above composition is made according to above-mentioned preparation method
Preparation, this group of preparation 0.638g standard, distilled water wiring solution-forming, 20mL/kg (body weight) warps are given per 1kg body weight according to mouse
Mouth gavage；
A9 groups：Lack rhodiola root, saline cistanche, barrenwort 80g, ginkgo leaf 40g；Above composition is made according to above-mentioned preparation method
Preparation, this group of preparation 0.638g standard, distilled water wiring solution-forming, 20mL/kg (body weight) warps are given per 1kg body weight according to mouse
Mouth gavage；
A10 groups：Lack barrenwort, rhodiola root, ginkgo leaf, saline cistanche 30g；Above composition is made according to above-mentioned preparation method
Agent, this group of preparation 0.638g standard is given per 1kg body weight according to mouse, distilled water wiring solution-forming, 20mL/kg (body weight) is orally
Gavage.
2.2 modellings and administration
150 ICR mouse are randomly divided into 15 groups, every group 10.Daily oral gavage gives each experimental group composition, blank
Group, model group give distilled water.After 30 days, model group and each experimental group are subjected to swimming test, blank group is to distilled water, observation
After put to death animal, take liver, eyeball takes blood to carry out hepatic glycogen, the measure of serum urea nitrogen.
2.3 Testing index
The assay of hepatic glycogen：Swim after 90min, disconnected neck, which is put to death, takes liver, is determined using anthrone method.
The measure of serum urea nitrogen：After swimming 90min, after eyeball blood sampling, using Beckman-Coulter CX5PRO types
Automatic clinical chemistry analyzer determines serum urea nitrogen content.
3. experimental result
3.1 animal typically shows
Before modeling, each group mouse can normal diet, body weight by the phase increase.After swimming test, model group, experimental mice step
State is unstable, hypoergia；And the naive mice for not carrying out swimming test moves freely, it is quick on the draw, hair luster
3.2 experimental result
Experimental data carries out data variance analysis with SPSS softwares, and each experimental group is entered compared with solvent control group with SNK methods
Row statistics.The experimental result of blank group, model group and each experimental group is shown in Table 1.
The anti-fatigue medicament of table 1 combination to mouse hepatic glycogen, serum urea nitrogen influence (N=10)
Note：Compared with blank group,#P<0.05,##P<0.01；Compared with model group,*P<0.05,**P<0.01。
As a result show, compared with blank group, hepatic glycogen content substantially reduces (P ＜ 0.01) model group.Take the present invention's
After anti-fatigue medicament combination 30d, the average hepatic glycogen content of high, medium and low content groups mouse is and high obviously higher than model group
In blank group.Through q' check analyses, for high, middle content groups mouse hepatic glycogen content apparently higher than model group, difference has statistics meaning
Adopted (P ＜ 0.05).Other experimental groups (A1-10) increase significantly compared with model group, compared with blank group, numerically connect
Closely.As a result the effect of anti-fatigue medicament combination of the present invention is with very strong increase human body glycogen deposit is shown, effect is better than not
Complete prescription (A1-10), it is optimal to illustrate the combination formula.
For model group compared with blank group, serum urea nitrogen content is significantly raised (P ＜ 0.01).Take the antifatigue of the present invention
After drug regimen 30d, the average serum urea nitrogen content of high, medium and low dosage mouse is significantly lower than model group, examines and divides through q'
Analysis, high, medium and low dosage mice serum urea nitrogen content are significantly lower than model group, statistically significant (P ＜ 0.01, the P ＜ of difference
0.05).Other experimental groups (A1-10) numerically approach compared with blank group.As a result the anti-fatigue medicament combination of the present invention is shown
Exercised rats serum urea nitrogen content can be significantly reduced, prompts it to increase the supply of animal self-energy, so as to reduce albumen
Matter catabolism energizes, and delays body sense of fatigue occur.
This result of the test also shows that the present composition is really optimum formula.The medicine group of high, medium and low dosage
Conjunction can greatly improve the hepatic glycogen content of mouse, while reduce serum urea nitrogen content, no matter high, medium and low dosage, numerically
Exceed not tired blank group；And incomplete prescription (A1-10) can allow mouse to return to and connect though also there is identical effect
Nearly blank group not tired level, but Comparatively speaking, effect is far away from said composition.
4. conclusion
In summary, fatigue-resistant drug composition of the invention can increase body glycogen deposit, so as to reduce protein
Catabolism energizes, and delays body sense of fatigue occur, has obvious anti-fatigue effect, it is possible to increase immunity of organisms, improves
Organism metabolism is horizontal, tolerance of the enhancing body in excess load, and the prescription of 4 taste medicines is significantly better than 3 tastes and 2 herbal medicines
The effect of prescription, therefore the fatigue-resistant drug composition of 4 taste medicine composition is expected to develop.
Embodiment：
Concrete technical scheme of the invention described further below, in order to which those skilled in the art further understands this
Invention, without forming the limitation to its right.
Embodiment 1：A kind of preparation of fatigue-resistant drug composition
Barrenwort 80g, rhodiola root 50g, ginkgo leaf 40g, saline cistanche 30g raw materials after pulverizing and sieving add 1.6L decoctings
Boil extraction 1 time, 0.5 hour every time, filtering, merging filtrate, be concentrated under reduced pressure relative density be 1.1 medicinal extract；Gained medicinal extract
At a temperature of 40 DEG C reduced vacuum it is dry dry extract, crushed 80 mesh sieves, produce fatigue-resistant drug composition.
Embodiment 2：A kind of preparation of fatigue-resistant drug composition
Barrenwort 80g, rhodiola root 50g, ginkgo leaf 40g, saline cistanche 30g raw materials after pulverizing and sieving add 2.0L decoctings
Boil extraction 2 times, 1.5 hours every time, filtering, merging filtrate, be concentrated under reduced pressure relative density be 1.3 medicinal extract；Gained medicinal extract
At a temperature of 70 DEG C reduced vacuum it is dry dry extract, crushed 90 mesh sieves, produce fatigue-resistant drug composition.
Embodiment 3：A kind of preparation of fatigue-resistant drug composition
Barrenwort 80g, rhodiola root 50g, ginkgo leaf 40g, saline cistanche 30g raw materials after pulverizing and sieving add 2.4L decoctings
Boil extraction 3 times, 2 hours every time, filtering, merging filtrate, be concentrated under reduced pressure relative density be 1.5 medicinal extract；Gained medicinal extract exists
At a temperature of 100 DEG C reduced vacuum it is dry dry extract, crushed 100 mesh sieves, produce fatigue-resistant drug composition.
Embodiment 4：A kind of preparation of antifatigue decoction
Barrenwort 80g, rhodiola root 50g, ginkgo leaf 40g, saline cistanche 30g raw materials after pulverizing and sieving add 2L decoctings and boiled
Extraction 3 times, 1 hour, filtering, merging filtrate produce every time.
Embodiment 5：A kind of preparation of antifatigue granule
Barrenwort 80g, rhodiola root 50g, ginkgo leaf 40g, saline cistanche 30g raw materials after pulverizing and sieving add 2L 60%
Ethanol extracts 3 times, 1 hour every time, filtering, merging filtrate, be concentrated under reduced pressure relative density be 1.1 medicinal extract；Gained medicinal extract
At a temperature of 70 DEG C reduced vacuum it is dry dry extract, crushed 80 mesh sieves, obtain fatigue-resistant drug composition.Obtain antifatigue
Pharmaceutical composition and dextrin (5:1, mass ratio), mix, using 95% ethanol as adhesive, wet granulation is dried, and whole grain produces.
Embodiment 6：A kind of preparation of antifatigue
Barrenwort 80g, rhodiola root 50g, ginkgo leaf 40g, saline cistanche 30g raw materials after pulverizing and sieving add 2L 60%
Ethanol extracts 3 times, 1 hour every time, filtering, merging filtrate, be concentrated under reduced pressure relative density be 1.1 medicinal extract；Gained medicinal extract
At a temperature of 70 DEG C reduced vacuum it is dry dry extract, crushed 80 mesh sieves, obtain fatigue-resistant drug composition.Obtain antifatigue
Pharmaceutical composition and dextrin (5:1), mix, using 95% ethanol as adhesive, wet granulation, dry, whole grain, add 1% stearic acid
Magnesium, mix, tabletted, film coating, packaging, produce.
Claims (10)
1. a kind of antifatigue pharmaceutical composition, it is characterised in that be made up of the material medicine of following weight/mass percentage composition：Excessive sheep
The quality hundred of the leaves of pulse plants 3%~80%, rhodiola root 3%~70%, ginkgo leaf 3%~70%, saline cistanche 3%~70%, and each raw material
It is 100% to divide content sum.
2. antifatigue pharmaceutical composition as claimed in claim 1, it is characterised in that by the raw material of following weight/mass percentage composition
Medicine is made：Barrenwort 10%~60%, rhodiola root 10%~50%, ginkgo leaf 10%~50%, saline cistanche 10%~50%,
And the weight/mass percentage composition sum of each raw material is 100%.
3. antifatigue pharmaceutical composition as claimed in claim 2, it is characterised in that by the raw material of following weight/mass percentage composition
Medicine is made：Barrenwort 40%, rhodiola root 25%, ginkgo leaf 20%, saline cistanche 15%.
4. the antifatigue pharmaceutical composition according to Arbitrary Term in claims 1 to 3, it is characterised in that described is antifatigue
Pharmaceutical composition mainly by adding solvent after the raw material of formula ratio is pulverized and sieved, decoct, filter, being concentrated under reduced pressure to give leaching
Cream, the anti-Fatigue Composition described in drying to obtain.
5. the preparation method of the antifatigue pharmaceutical composition described in claim 1, it is characterised in that comprise the steps of：
(1) raw material is pulverized and sieved, adds Extraction solvent, and at 40~100 DEG C of temperature, extract 1~3 time, every time 0.5~3
Hour, obtain extract solution；Wherein the ratio between material quality and Extraction solvent volume are 1g：8~12mL；
(2) extract solution is merged, filtered, concentrated, spray-dried, reduced vacuum is dry or lyophilized, obtains dry extract；
(3) dry extract that will be obtained, crush, cross the mesh sieve of 80 mesh~100, produce described antifatigue pharmaceutical composition.
6. preparation method according to claim 5, it is characterised in that the Extraction solvent described in step (1) is selected from water or organic
Solvent, the preferred petroleum ether of described organic solvent, ethyl acetate, the one or more in chloroform and ethanol；Described extraction side
The preferred Microwave Extraction of method, refluxing extraction or means of supercritical extraction.
7. application of the antifatigue pharmaceutical composition in the medicine for preparing treatment apocamnosis described in claim 1.
8. a kind of medicine for being used to treat apocamnosis, it is characterised in that include the pharmaceutical composition described in claim 1.
9. medicine according to claim 8, it is characterised in that described medicine is the drug regimen described in claim 1
Thing is mixed with pharmaceutically acceptable auxiliary material, any one formulation clinically allowed being prepared.
10. medicine according to claim 9, it is characterised in that described formulation is selected from decoction, granule, capsule, piece
Agent, mixture, pill or powder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610688954.5A CN107753567B (en) | 2016-08-18 | 2016-08-18 | Anti-fatigue pharmaceutical composition and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610688954.5A CN107753567B (en) | 2016-08-18 | 2016-08-18 | Anti-fatigue pharmaceutical composition and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107753567A true CN107753567A (en) | 2018-03-06 |
| CN107753567B CN107753567B (en) | 2020-07-24 |
Family
ID=61262442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610688954.5A Active CN107753567B (en) | 2016-08-18 | 2016-08-18 | Anti-fatigue pharmaceutical composition and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107753567B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114304067A (en) * | 2022-02-03 | 2022-04-12 | 兰州大学 | Method for establishing compound-factor-induced fatigue mouse model and anti-fatigue composition |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102872206A (en) * | 2012-10-12 | 2013-01-16 | 中国医学科学院药用植物研究所云南分所 | Traditional Chinese medicine compound capable of improving immunity, resisting fatigue and improving sexual function |
-
2016
- 2016-08-18 CN CN201610688954.5A patent/CN107753567B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102872206A (en) * | 2012-10-12 | 2013-01-16 | 中国医学科学院药用植物研究所云南分所 | Traditional Chinese medicine compound capable of improving immunity, resisting fatigue and improving sexual function |
Non-Patent Citations (2)
| Title |
|---|
| 刘雨生等: "脑轻松致躁狂症1例报告", 《临床精神医学杂志》 * |
| 吴丽霞等: "肉苁蓉与淫羊藿提取物对小鼠抗疲劳作用研究", 《国际医药卫生导报》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114304067A (en) * | 2022-02-03 | 2022-04-12 | 兰州大学 | Method for establishing compound-factor-induced fatigue mouse model and anti-fatigue composition |
| CN114304067B (en) * | 2022-02-03 | 2024-01-09 | 兰州大学 | Method for establishing compound factor fatigue-induced mouse model and anti-fatigue composition |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107753567B (en) | 2020-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101002858A (en) | Medicine composition for enhancing immunity, and its preparing method and use | |
| CN108042627B (en) | Composition for treating hyperuricemia and preparation method and application thereof | |
| CN104922176B (en) | A kind of application of Flos Chrysanthemi Indici extract | |
| CN105919136A (en) | Nutrition supplement composition with fatigue resisting and immunity improving effects and preparation and preparation method thereof | |
| CN101033245B (en) | Preparation method and application of pedunculoside | |
| CN105832794A (en) | Application of Gynura procumbens to production of medicine, healthcare food or functional food for preventing and treating hyperuricemia | |
| CN103432184A (en) | Application of great burdock fruit extract in drug production or foods | |
| CN104997883A (en) | Inonotus obliquus raspberry tree red raspberry composition, inonotus obliquus raspberry tree red raspberry composite oral solution and preparation method and application thereof | |
| CN104523742B (en) | A kind of polysaccharide composition and its application with protect liver and raising immunization | |
| CN104257811B (en) | A kind of food, health products or pharmaceutical composition protected the liver | |
| CN101433595A (en) | Desertliving cistanche alcohol extract as well as preparation method and use thereof | |
| CN107753567A (en) | A kind of fatigue-resistant drug composition and preparation method and application | |
| CN104286844B (en) | A kind of improve the food of immunity, health product or pharmaceutical composition | |
| CN102579530A (en) | Preparation method of aralia taibaiensis total saponin having diabetes mellitus resisting effect and medicament | |
| CN105796625A (en) | Pharmaceutical composition containing red yeast rice and safflower and preparation thereof | |
| CN103877323B (en) | Medicinal composition for treating non-alcoholic fatty liver disease | |
| CN102858359A (en) | Medicinal composition comprising alcohol-soluble and water-insoluble licorice extract, pharmaceutical preparation, pharmaceutical application, therapeutic method, and preparative method thereof | |
| CN101721455A (en) | Manyflower tickclove herb extract, and preparation method and application thereof | |
| CN104547499A (en) | Traditional Chinese medicine composition for treating diabetic nephropathy and atherosclerosis | |
| CN108704036A (en) | A kind of Chinese traditional compound medicine and preparation method thereof for treating gout | |
| CN102973898A (en) | Traditional Chinese medicine compound extract for treating chronic pharyngolaryngitis and preparation thereof | |
| CN104056020B (en) | A kind of Chinese medicine composition for treating metabolic syndrome | |
| CN107582898A (en) | A kind of antibechic stops pharmaceutical composition of phlegm and its production and use | |
| CN102008588B (en) | Medicine composition for curing hepatic encephalopathy and hepatitis B | |
| CN110536690A (en) | For preventing or treating the pharmaceutical compositions of infection with hepatitis C virus disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20190506 Address after: 222047 Jiangning Industrial City, Lianyungang Economic and Technological Development Zone, Jiangsu Province Applicant after: Kangyuan Pharmceutical Co., Ltd. Applicant after: JIANGSU KANION YANGGUANG PHARMACEUTICAL CO., LTD. Address before: 222047 Jiangning Industrial City, Lianyungang Economic and Technological Development Zone, Jiangsu Province Applicant before: Kangyuan Pharmceutical Co., Ltd. |
|
| TA01 | Transfer of patent application right | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |